Naltrexone SR 32 mg/bupropion SR 360 mg/day

DRUG2 trials

Sponsors

Orexigen Therapeutics, Inc

Conditions

ObesityOverweight

Phase 2

A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects

CompletedNCT00711477

Orexigen Therapeutics, IncObesity

Start: 2008-09-30End: 2010-06-30Updated: 2015-01-06

Phase 3

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects

CompletedNCT00567255

Orexigen Therapeutics, IncObesity, Overweight

Start: 2007-12-31End: 2009-06-30Updated: 2014-11-21